Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Ultragenyx Pharmaceutical (NASDAQ: RARE) announced the grant of 20,820 restricted stock units to 13 newly hired non-executive officers. The compensation committee approved these awards under the Ultragenyx Employment Inducement Plan, with a grant date of November 16, 2024. The stock units will vest over four years, with 25% of shares vesting annually, contingent on continuous employment. This grant was made in accordance with Nasdaq Listing Rule 5635(c)(4) as an employment inducement.
Ultragenyx Pharmaceutical (NASDAQ: RARE) ha annunciato l'assegnazione di 20.820 unità di azioni vincolate a 13 nuovi funzionari non esecutivi. Il comitato per la remunerazione ha approvato questi premi nell'ambito del Piano di Induzione all'Occupazione Ultragenyx, con una data di concessione fissata al 16 novembre 2024. Le unità di azioni saranno mature in un periodo di quattro anni, con il 25% delle azioni che matura annualmente, a condizione di un impiego continuativo. Questa concessione è stata effettuata in conformità alla Regola di Quotazione del Nasdaq 5635(c)(4) come incentivo all'occupazione.
Ultragenyx Pharmaceutical (NASDAQ: RARE) anunció la concesión de 20,820 unidades de acciones restringidas a 13 oficiales no ejecutivos recién contratados. El comité de compensación aprobó estos premios bajo el Plan de Inducción al Empleo de Ultragenyx, con una fecha de concesión del 16 de noviembre de 2024. Las unidades de acciones se adquirirán durante cuatro años, con el 25% de las acciones adquiriéndose anualmente, condicionado a un empleo continuo. Esta concesión se realizó de acuerdo con la Regla de Cotización del Nasdaq 5635(c)(4) como un incentivo de empleo.
Ultragenyx 제약 (NASDAQ: RARE)은 13명의 새로 고용한 비정규 임원에게 20,820 제한 주식 단위를 수여한다고 발표했습니다. 보상 위원회는 Ultragenyx 고용 유도 계획에 따라 이러한 상을 승인했으며, 부여 날짜는 2024년 11월 16일입니다. 주식 단위는 4년 동안 만기되며, 연간 25%의 주식이 만기되며 지속적인 고용에 조건이 있습니다. 이 부여는 Nasdaq 상장 규정 5635(c)(4)에 따라 고용 유도로 이루어졌습니다.
Ultragenyx Pharmaceutical (NASDAQ: RARE) a annoncé l'octroi de 20 820 unités d'actions restreintes à 13 nouveaux cadres non exécutifs. Le comité de rémunération a approuvé ces récompenses dans le cadre du Plan d'Incitation à l'Emploi d'Ultragenyx, avec une date d'octroi fixée au 16 novembre 2024. Les unités d'actions seront acquises sur une période de quatre ans, avec 25 % des actions acquises chaque année, sous réserve d'un emploi continu. Cet octroi a été effectué conformément à la Règle de Cotation du Nasdaq 5635(c)(4) en tant qu'incitation à l'emploi.
Ultragenyx Pharmaceutical (NASDAQ: RARE) gab die Gewährung von 20.820 eingeschränkten Aktieneinheiten an 13 neu eingestellte nicht-executive Mitarbeiter bekannt. Der Vergütungsausschuss genehmigte diese Auszeichnungen im Rahmen des Ultragenyx Employment Inducement Plans, mit einem Gewährungsdatum vom 16. November 2024. Die Aktieneinheiten werden über vier Jahre verteilt, wobei 25 % der Anteile jährlich fällig werden, vorausgesetzt es besteht ein kontinuierliches Arbeitsverhältnis. Diese Gewährung erfolgte gemäß der Nasdaq-Listing-Regel 5635(c)(4) als Beschäftigungsanreiz.
- None.
- None.
NOVATO, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare diseases, today reported the grant of 20,820 restricted stock units of the company’s common stock to 13 newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company’s board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of November 16, 2024, as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4).
The restricted stock units vest over four years, with
About Ultragenyx Pharmaceutical Inc.
Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultrarare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com.
Contact Ultragenyx
Investors & Media
Joshua Higa
(415) 475-6370
FAQ
How many restricted stock units did Ultragenyx (RARE) grant on November 16, 2024?
What is the vesting schedule for Ultragenyx's (RARE) November 2024 restricted stock units?
Under which rule did Ultragenyx (RARE) grant the November 2024 stock units?
